Answers are grounded in this paper and cite their sources.
Demonstrates PIA evaluation improves agreement in genomic variant interpretation, suggesting more reliable AI assessments.
Agentic AI systems are non-deterministic - the same task executed twice may follow entirely different reasoning paths. Standard evaluation metrics, designed for single-turn text generation, break under this condition: inter-rater agreement collapses when evaluators compare different execution paths rather than equivalent ones. We introduce Path-Invariant Agreement (PIA), a trajectory-level consistency metric that measures evaluation agreement independent of path variation. Empirical validation shows PIA achieves kappa = +0.743 inter-rater reliability versus kappa = -0.065 for standard path-comparison baselines (delta = +0.808). Applied to quantization sensitivity analysis on Mistral-7B, PIA detects an 11.9% trajectory quality degradation at INT4 GPTQ precision that standard perplexity benchmarks miss entirely, with planning quality declining 14.9% and error recovery declining 20.0% while goal alignment remains stable. To demonstrate applicability in high-stakes real-world domains, we apply the PIA evaluation pipeline to clinical genomic variant interpretation: running Evo2-40B and ESMFold on eight Indian HBB variants responsible for beta-thalassemia burden in South Asia, a population critically underrepresented in existing genomic benchmarks. ESMFold pLDDT scores reveal a systematic structural divergence between pathogenic variants (mean pLDDT 85.4-88.4) and wildtype (pLDDT 69.9), reflecting truncation-induced compaction rather than instability - a biologically interpretable signal that PIA-based evaluation can be designed to capture. All code, datasets, and interactive dashboards are publicly available.
No takes yet. Share an insight, caveat, or question.
Shailendra Bade (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: